Korean J Urol.  2013 Feb;54(2):106-110.

Efficacy of Alfuzosin After Shock Wave Lithotripsy for the Treatment of Ureteral Calculi

• Cho HJ
• Shin SC
• Seo DY
• Min DS
• Cho JM
• Kang JY
• Yoo TK

Abstract

PURPOSE
We evaluated the efficacy of alfuzosin for the treatment of ureteral calculi less than 10 mm in diameter after extracorporeal shock wave lithotripsy (ESWL).
MATERIALS AND METHODS
A randomized, single-blind clinical trial was performed prospectively by one physician between June 2010 and August 2011. A total of 84 patients with ureteral calculi 5 to 10 mm in diameter were divided into two groups. Alfuzosin 10 mg (once daily) and loxoprofen sodium 68.1 mg (as needed) were prescribed to group 1 (n=41), and loxoprofen sodium 68.1 mg (as needed) only was prescribed to group 2 (n=44). The drug administration began immediately after ESWL and continued until stone expulsion was confirmed up to a maximum of 42 days after the procedure.
RESULTS
Thirty-nine of 41 (95.1%) patients in group 1 and 40 of 43 (93.0%) patients in group 2 ultimately passed stones (p=0.96). The number of ESWL sessions was 1.34+/-0.65 and 1.41+/-0.85 in groups 1 and 2, respectively (p=0.33). The patients who required analgesics after ESWL were 8 (19.5%) in group 1 and 13 (30.2%) in group 2 (p=0.31). Visual analogue scale pain severity scores were 5.33+/-1.22 and 6.43+/-1.36 in groups 1 and 2, respectively (p=0.056). The time to stone expulsion in groups 1 and 2 was 9.5+/-4.8 days and 14.7+/-9.8 days, respectively (p=0.005). No significant adverse effects occurred.
CONCLUSIONS
The use of alfuzosin in combination with ESWL seems to facilitate stone passage and to reduce the time of stone expulsion but does not affect the stone-free rate.

Keyword

Alfuzosin; Lithortripsy; Urolithiasis

MeSH Terms

Analgesics
Humans
Lithotripsy
Phenylpropionates
Prospective Studies
Quinazolines
Shock
Sodium
Ureter
Ureteral Calculi
Urolithiasis
Analgesics
Phenylpropionates
Quinazolines
Sodium

Reference

1. Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al. Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association. J Urol. 1997. 158:1915–1921.

2. Eisner BH, Reese A, Sheth S, Stoller ML. Ureteral stone location at emergency room presentation with colic. J Urol. 2009. 182:165–168.

3. Kijvikai K, Haleblian GE, Preminger GM, de la Rosette J. Shock wave lithotripsy or ureteroscopy for the management of proximal ureteral calculi: an old discussion revisited. J Urol. 2007. 178(4 Pt 1):1157–1163.

4. Sayed MA, el-Taher AM, Aboul-Ella HA, Shaker SE. Steinstrasse after extracorporeal shockwave lithotripsy: aetiology, prevention and management. BJU Int. 2001. 88:675–678.

5. Resim S, Ekerbicer HC, Ciftci A. Role of tamsulosin in treatment of patients with steinstrasse developing after extracorporeal shock wave lithotripsy. Urology. 2005. 66:945–948.

6. Kobayashi S, Tomiyama Y, Maruyama K, Hoyano Y, Yamazaki Y, Kusama H. Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters. J Smooth Muscle Res. 2009. 45:187–195.

7. Park HK, Choi EY, Jeong BC, Kim HH, Kim BK. Localizations and expressions of alpha-1A, alpha-1B and alpha-1D adrenoceptors in human ureter. Urol Res. 2007. 35:325–329.

8. Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006. 368:1171–1179.

9. Parsons JK, Hergan LA, Sakamoto K, Lakin C. Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol. 2007. 177:983–987.

10. Singh A, Alter HJ, Littlepage A. A systematic review of medical therapy to facilitate passage of ureteral calculi. Ann Emerg Med. 2007. 50:552–563.

11. Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K. Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol. 2007. 14:749–753.

12. Kupeli B, Irkilata L, Gurocak S, Tunc L, Kirac M, Karaoglan U, et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy? Urology. 2004. 64:1111–1115.

13. Kobayashi M, Naya Y, Kino M, Awa Y, Nagata M, Suzuki H, et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. Int J Urol. 2008. 15:495–498.

14. Falahatkar S, Khosropanah I, Vajary AD, Bateni ZH, Khosropanah D, Allahkhah A. Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi? J Endourol. 2011. 25:495–498.

15. Wang H, Liu K, Ji Z, Li H. Effect of alpha1-adrenergic antagonists on lower ureteral stones with extracorporeal shock wave lithotripsy. Asian J Surg. 2010. 33:37–41.

16. Gravas S, Tzortzis V, Karatzas A, Oeconomou A, Melekos MD. The use of tamsulozin as adjunctive treatment after ESWL in patients with distal ureteral stone: do we really need it? Results from a randomised study. Urol Res. 2007. 35:231–235.

17. Pedro RN, Hinck B, Hendlin K, Feia K, Canales BK, Monga M. Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study. J Urol. 2008. 179:2244–2247.

18. Chau LH, Tai DC, Fung BT, Li JC, Fan CW, Li MK. Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10 mm: a prospective randomized controlled trial. Int J Urol. 2011. 18:510–514.

19. Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol. 2005. 173:2010–2012.

20. Ahmed AF, Al-Sayed AY. Tamsulosin versus alfuzosin in the treatment of patients with distal ureteral stones: prospective, randomized, comparative study. Korean J Urol. 2010. 51:193–197.

21. Cha WH, Choi JD, Kim KH, Seo YJ, Lee K. Comparison and efficacy of low-dose and standard-dose tamsulosin and alfuzosin in medical expulsive therapy for lower ureteral calculi: prospective, randomized, comparative study. Korean J Urol. 2012. 53:349–354.

22. Itoh Y, Okada A, Yasui T, Hamamoto S, Hirose M, Kojima Y, et al. Efficacy of selective α1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011. 18:672–674.

23. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate. 1997. 33:55–59.

24. Grasso M, Fortuna F, Lania C, Blanco S. Ejaculatory disorders and alpha1-adrenoceptor antagonists therapy: clinical and experimental researches. J Transl Med. 2006. 4:31.

25. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003. 92:257–261.

26. Hofner K, Jonas U. Alfuzosin: a clinically uroselective alpha1-blocker. World J Urol. 2002. 19:405–412.

27. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998. 51:892–900.

28. Narayan P, Bruskewitz R. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv Ther. 2000. 17:287–300.

29. Moriyama N, Nasu K, Takeuchi T, Akiyama K, Murata S, Nishimatsu H, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions. Br J Pharmacol. 1997. 122:1009–1014.

30. Giuliano F, Allard F, McKenna K, Jardin A, Benoit G, Bernabe J. Tamsulosin has more deleterious effects than alfuzosin on parameters characterizing ejaculation in anaesthetized rats [abstract]. Int J Impot Res. 2002. 14:suppl 3. S12.